Global Myeloma Voices Come Together to Drive Research and Improve Lives of Patients

Madrid BlogThis past week was very busy and important for the global myeloma community, which is increasingly coming together with a single voice for myeloma research and patient care. In Madrid, Spain, on the eve of the 2017 Congress of the European Hematology Association, the IMF provided platforms for many of these global research voices at the 2017 International Myeloma Working Group® (IMWG) Summit, as well as during the regular research update meeting of the IMF Black Swan Research Initiative® investigators team.

PET/CT Scanning Comes of Age: New IMWG Guidelines Published

New IMWG guidelines for PET/CT scanning have been published inThe Lancet Oncology. In his blog this week, IMF Chairman Dr. Brian Durie congratulates Dr. Michele Cavo and his team for their report on this extremely accurate imaging technique, used to establish a diagnosis and to monitor throughout the course of the disease. “The new IMWG guidelines provide a comprehensive review of the current role and optimal uses of FDG PET/ CT scanning,” he writes.

International Myeloma Workshop: the spirit of India and the emerging myeloma community

The 16th International Myeloma Workshop was held in New Delhi, India March 1-4. This gathering of those interested in myeloma from around the world was definitely a global amalgam. The format included multiple short presentations to encompass the full range of scientific and clinical topics.

Is MRD testing ready for “prime time”?

The answer is a definite yes and no! Yes, it is now a priority to test for minimal residual disease (MRD) in myeloma clinical trials. However, no, MRD testing is not yet recommended in routine clinical practice.  But I’m pleased to report that we are getting there.

7th Annual International Myeloma Working Group (IMWG) Summit a big success

Synergy at the 7th Annual IMWG Summit was the hallmark of this year’s event in Copenhagen, Denmark. Despite very tight scheduling—many key speakers flew directly from the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago—the level of engagement and collaboration was remarkable. “I feel a strong sense of myeloma community,” observed Prof. Philippe Moreau, an IMWG Summit co-chairman. “The top myeloma investigators in the world all working together to achieve common goals.”

Pages